Management of primary retroperitoneal synovial sarcoma: A case report and review of literature

作     者：Aikaterini Mastoraki Dimitrios Schizas Ioannis S Papanikolaou George Bagias Nikolaos Machairas George Agrogiannis Theodore Liakakos Nikolaos Arkadopoulos 

作者机构：4th Department of SurgeryNational and Kapodistrian University of Athens Attikon University Hospital 1st Department of Surgery National and Kapodistrian University of Athens Laikon Hospital Hannover Medical School Clinic for General Visceral and Transplant Surgery 3rd Department of Surgery National and Kapodistrian University of Athens Attikon University Hospital 1st Department of Pathology National and Kapodistrian University of Athens 

出 版 物：《World Journal of Gastrointestinal Surgery》 (世界胃肠外科杂志（英文版）（电子版）)

年 卷 期：2019年第11卷第1期

页      面：27-33页

核心收录：

学科分类：10[医学] 

主　　题：Retroperitoneal tumours Synovial sarcoma Case report Clinical presentation Diagnostic modalities Therapeutic management 

摘      要：BACKGROUND Synovial sarcoma(SS) is a rare type of soft tissue sarcoma that is usually developed from areas where synovial tissue exists, especially at the ***, several cases of retroperitoneal SS(RSS) have been described. We herein report a case of RSS presented in our *** SUMMARY A 69-year-old female patient was admitted with a large, palpable, firm mass in the right abdominal space SS. Computerized tomography scan depicted a concentric, sharply marinated retro-peritoneal lesion which was displacing the right kidney and the lower edge of the liver. Subsequently, the patient underwent surgical excision of the mass with additional right nephrectomy and resection of the right adrenal gland and a part of the diaphragm. The final histological diagnosis of the tumour was grade II monophasic *** RSS is encountered in the biphasic type, the monophasic fibrous, and the monophasic epithelial category as well. Relevant clinical manifestations are not always documented at early stages. Therefore, the final diagnosis is posed after complete histological examination taking into consideration the results of immunochemistry and genetic analysis. Therapeutic approach happens often late when metastases at the lungs and the liver are apparent. Thus, 5-year survival rates remain low.